ophthalmic drugs market 2014-2024

Ophthalmic Drugs Market Forecast 2014-2024

Prospects for Leading Companies

©noticeThis material is copyright by visiongain. It is against the law to reproduce any of this material without the prior written agreement of visiongain. You cannot photocopy, fax, download to database or duplicate in any other way any of the material contained in this report. Each purchase and single copy is for personal use only.

www.visiongain.com

Contents

1. Report Overview

1.1 Global Ophthalmic Drugs Market Overview

1.2 Global Ophthalmic Drugs Market Segmentation

1.3 Why You Should Read This Report

1.4 How This Report Delivers

1.5 Key Questions Answered by This Analytical Report

1.6 Who is This Report For?

1.7 Methodology

1.8 Frequently Asked Questions (FAQ)

1.9 Associated Visiongain Reports

1.10 About Visiongain

2. Introduction to Ophthalmic Drugs

2.1 The Pharmaceutical Industry: a Very Brief Overview

2.2 The Eye: An Overview of Its Structure and Function

2.3 The Global Burden of Eye Disease

2.4 Ophthalmic Drugs: Market Segmentation

2.5 Glaucoma: the ‘Silent Thief of Sight’

2.5.1 A Classification of Glaucoma

2.5.1.1 Primary Open-Angle Glaucoma

2.5.1.2 Acute Angle-Closure Glaucoma

2.5.1.3 Congenital Glaucoma

2.5.1.4 Secondary Glaucoma

1. Report Overview

2. Introduction to Ophthalmic Drugs

www.visiongain.com

Contents

2.5.1.5 Normal-Tension Glaucoma

2.5.1.6 Ocular Hypertension

2.5.2 Risk Factors for Glaucoma

2.5.3 Diagnosis of Glaucoma

2.5.4 Drug Treatment of Glaucoma

2.5.5 Laser Treatment and Surgery for Glaucoma

2.6 Age-Related Macular Degeneration (AMD)

2.6.1 Dry (non-exudative) AMD

2.6.2 Wet (exudative) AMD

2.6.3 Risk Factors for AMD

2.6.4 Diagnosis of AMD

2.6.5 Treatment of AMD

2.7 Diabetic Retinopathy (DR)

2.7.1 Diagnosis of Diabetic Retinopathy

2.7.2 Treatment of Diabetic Retinopathy

2.8 Ocular Allergy and Allergic Conjunctivitis

2.8.1 Diagnosis of Ocular Allergy

2.8.2 Treatment of Ocular Allergy

2.9 Ocular Inflammatory Disease

2.9.1 Treatment of Ocular Inflammatory Disease

2.10 Eye Infections

2.10.1 Treatment of Eye Infections

2.11 Dry Eye Syndrome

2.11.1 Treatment of Dry Eye Syndrome

www.visiongain.com

Contents

2.12 Phases of Clinical Trials

2.13 Scope of this Report

2.14 Currency Exchange Rates in This Report

3. Ophthalmic Drugs: World Market 2014-2024

3.1 The World Ophthalmic Drugs Market in 2013

3.1.1 Leading Ophthalmic Drugs

3.1.2 Leading Companies in the Ophthalmic Drugs Market

3.2 World Ophthalmic Drugs Market: Sales Forecast 2014-2024

3.3 Retinal Disorder Drugs Lead the World Ophthalmic Drugs Market

3.4 How Will Segmental Market Shares Change to 2024?

3.4.1 World Ophthalmic Drugs Market: Drivers and Restraints 2014-2024

4. Leading National Markets 2014-2024

4.1 Geographical Breakdown of the World Ophthalmic Drugs Market

4.2 World Ophthalmic Drugs Market: National Markets Forecast 2014-2024

4.2.1 How Will National Market Shares Change to 2024?

4.3 The US Ophthalmic Drugs Market 2014-2024

4.3.1 US Ophthalmic Drugs Market Forecast 2014-2024

4.3.2 US Ophthalmic Drugs Market: Trends and Developments

4.3.2.1 Affordable Care Act: Expanding Medicare Coverage

4.3.2.2 A US Biosimilars Market?

4.4 Japanese Ophthalmic Drugs Market 2014-2024

3. Ophthalmic Drugs: World Market 2014-2024

4. Leading National Markets 2014-2024

www.visiongain.com

Contents

4.4.1 Japanese Ophthalmic Drugs Market Forecast 2014-2024

4.4.2 Japanese Ophthalmic Drugs Market: Trends and Developments

4.4.2.1 The Cost of Treatment in Japan

4.5 Chinese Ophthalmic Drugs Market 2014-2024

4.5.1 Chinese Ophthalmic Drugs Market Forecast 2014-2024

4.5.2 Chinese Ophthalmic Drugs Market: Trends and Developments

4.5.2.1 Expansion of Healthcare Coverage and Reimbursement

4.5.2.2 Price Controls and the Anhui Model

4.6 EU5 Ophthalmic Drugs Market 2014-2024

4.6.1 German Ophthalmic Drugs Market Forecast 2014-2024

4.6.2 French Ophthalmic Drugs Market Forecast 2014-2024

4.6.3 UK Ophthalmic Drugs Market Forecast 2014-2024

4.6.4 Italian Ophthalmic Drugs Market Forecast 2014-2024

4.6.5 Spanish Ophthalmic Drugs Market Forecast 2014-2024

4.7 Brazilian Ophthalmic Drugs Market 2014-2024

4.7.1 Brazilian Ophthalmic Drugs Market Forecast 2014-2024

4.7.2 Brazilian Ophthalmic Drugs Market: Trends and Developments

4.7.2.1 Increasing Access to Medicines

4.8 Russian Ophthalmic Drugs Market 2014-2024

4.8.1 Russian Ophthalmic Drugs Market Forecast 2014-2024

4.8.2 Russian Ophthalmic Drugs Market: Trends and Developments

4.8.2.1 Pharma2020, Healthcare and Industry Reform

4.9 Indian Ophthalmic Drugs Market 2014-2024

4.9.1 Indian Ophthalmic Drugs Market Forecast 2014-2024

www.visiongain.com

Contents

4.9.2 Indian Ophthalmic Drugs Market: Trends and Developments

4.9.2.1 Drug Prices Control Order 2013

4.9.2.2 Expansion of Healthcare Provision

4.10 Mexican Ophthalmic Drugs Market 2014-2024

4.10.1 Mexican Ophthalmic Drugs Market Forecast 2014-2024

4.10.2 Mexican Ophthalmic Drugs Market: Trends and Developments

4.10.2.1 Lupin Acquires Laboratorios Grin, Entering the Mexican Market

4.10.2.2 Seguro Popular: Mexican Healthcare Reform

4.10.2.3 International Interest in Mexico

5. Retinal Disorder Drugs Market 2014-2024

5.1 Retinal Disorder Drugs: the Rise of Anti-VEGF Therapy

5.2 Leading Retinal Disorder Drugs in 2013

5.3 Retinal Disorder Drugs: Market Forecast 2014-2024

5.4 Market Share of Leading Retinal Disorder Drugs to 2024

5.5 Retinal Disorder Drugs: Trends and Developments

5.5.1 Lucentis Dominates the Retinal Disorder Drugs Market

5.5.2 Roche and Novartis Fined Over Lucentis-Avastin Collusion

5.5.3 Requiring Avastin Use in AMD?

5.5.4 Novartis Licenses Ophthotech’s Fovista

5.5.5 Jetrea Launch Disappoints Analysts

5.5.6 Conbercept Approved in China

5.5.7 Drug/Device Combination Products Entering the Market

5.5.8 Advances in Regenerative Medicine

5. Retinal Disorder Drugs Market 2014-2024

www.visiongain.com

Contents

5.6 Lucentis (ranibizumab, Roche/Novartis)

5.6.1 Lucentis: Sales Forecast 2014-2024

5.6.2 Less Frequent Dosing Approved in US

5.6.3 New Indications for Lucentis

5.6.4 Lucentis/Fovista Combination Therapy?

5.7 Eylea (aflibercept, Regeneron/Bayer/Santen)

5.7.1 Eylea: Sales Forecast 2014-2024

5.7.2 The Comparative Efficacy of Eylea

5.7.3 Combination Therapy with Eylea and a PDGFR-beta Inhibitor

5.8 Avastin (bevacizumab, Roche)

5.8.1 Avastin: Sales Forecast 2014-2024

5.8.2 Compounding Pharmacies and Safety Risks

5.9 Visudyne (verteporfin, Valeant/Novartis)

5.9.1 Visudyne: Sales Forecast 2014-2024

5.10 Jetrea (ocriplasmin, ThromboGenics/Novartis)

5.10.1 Jetrea: Sales Forecast 2014-2024

5.10.2 Potential Acquisition of ThromboGenics?

5.10.3 R&D Agreements with Eleven Biotherapeutics and Bicycle Therapeutics

5.11 Other Retinal Disorder Drugs

5.11.1 Iluvien (fluocinolone implant, Alimera Sciences)

5.11.2 Ozurdex (dexamethasone implant, Allergan)

6. Allergic, Inflammatory and Infective Drugs Market 2014-2024

6.1 Allergic, Inflammatory and Infective Drugs: Introduction

6. Allergic, Inflammatory and Infective Drugs Market 2014-2024

www.visiongain.com

Contents

6.2 Allergic, Inflammatory and Infective Drugs: Submarket Breakdown

6.3 Leading Allergic, Inflammatory and Infective Drugs in 2013

6.4 Allergic, Inflammatory and Infective Drugs: Market Forecast 2014-2024

6.5 Market Share of Leading Allergic, Inflammatory and Infective Drugs to 2024

6.6 Allergic, Inflammatory and Infective Drugs: Trends and Developments

6.6.1 Growth Prospects in 2014-2024

6.6.2Lupin Launches Generic Zymaxid

6.6.3 New Topical NSAIDs Launched: Prolensa and Ilevro

6.7 Patanol and Pataday (olopatadine, Alcon)

6.7.1 Patanol: Sales Forecast 2014-2024

6.7.2 Pataday: Sales Forecast 2014-2024

6.7.3 Generic Competition for Patanol/Pataday?

6.8 Vigamox (moxifloxacin, Alcon)

6.8.1 Vigamox: Sales Forecast 2014-2024

6.8.2 Generic Challenges to Vigamox

6.8.3 Moxeza: A Next-Generation Form of Vigamox

6.9 TobraDex (tobramycin/dexamethasone, Alcon)

6.9.1 TobraDex: Sales Forecast 2014-2024

6.9.2 TobraDex ST (Alcon/Novartis)

6.10 Bromday (bromfenac, Valeant)

6.10.1 Bromday: Sales Forecast 2014-2024

6.10.2 Prolensa: A New Formulation of Bromfenac

6.10.3 Competition from Ilevro/Nevanac

6.11 Cravit (levofloxacin, Santen)

www.visiongain.com

Contents

6.11.1 Cravit: Sales Forecast 2014-2024

6.12 Acular (ketorolac, Allergan)

6.12.1 Acular: Sales Forecast 2014-2024

6.13 AzaSite (azithromycin, Akorn)

6.13.1 AzaSite: Sales Forecast 2014-2024

7. Glaucoma Drugs Market 2014-2024

7.1 Glaucoma: Prostaglandin Analogues Lead the Market

7.2 Leading Glaucoma Drugs in 2013

7.3 Glaucoma Drugs: Market Forecast 2014-2024

7.4 Market Share of Leading Glaucoma Drugs to 2024

7.5 Glaucoma Drugs: Trends and Developments

7.5.1 Revenues Threatened by Patent Expiration

7.5.2 Preservative-Free Formulation Trends

7.5.3 Innovation in Treatments for Glaucoma

7.5.4 Simbrinza Launched as First Beta-Blocker-Free Combination

7.6 Lumigan and Ganfort (bimatoprost, Allergan)

7.6.1 Lumigan and Ganfort: Sales Forecast 2014-2024

7.7 Xalatan and Xalacom (latanoprost, Pfizer)

7.7.1 Xalatan/Xalacom: Sales Forecast 2014-2024

7.8 Travatan/Travatan Z and DuoTrav (travoprost, Novartis)

7.8.1 Travatan/Travatan Z and DuoTrav: Sales Forecast 2014-2024

7.9 Alphagan/Alphagan P and Combigan (brimonidine, Allergan)

7.9.1 Alphagan/Alphagan P and Combigan: Sales Forecast 2014-2024

7. Glaucoma Drugs Market 2014-2024

www.visiongain.com

Contents

7.10 Trusopt and Cosopt/Cosopt PF (dorzolamide, Merck)

7.10.1 Trusopt: Sales Forecast 2014-2024

7.10.2 Cosopt and Cosopt PF: Sales Forecast 2014-2024

7.11 Azopt (brinzolamide, Novartis)

7.11.1 Azopt: Sales Forecast 2014-2024

7.12 Tapros (tafluprost, Santen)

7.12.1 Tapros/Taflotan: Sales Forecast 2014-2024

7.13 Zioptan (tafluprost, Akorn)

7.13.1 Zioptan: Sales Forecast 2014-2024

8. Dry Eye Drugs Market 2014-2024

8.1 Dry Eye: Introduction

8.2 Leading Dry Eye Drugs in 2013

8.3 Dry Eye Drugs: Market Forecast 2014-2024

8.4 Market Share of Leading Dry Eye Drugs to 2024

8.5 Dry Eye Drugs: Trends and Developments

8.5.1 Will Generic Restasis Launch in 2014?

8.5.2 Intensive Research Focus on Dry Eye

8.5.3 Improving Diagnostic Tools

8.6 Restasis (ciclosporin, Allergan)

8.6.1 Restasis: Sales Forecast 2014-2024

8.7 Refresh Brand Products (Allergan)

8.7.1 Refresh Brand Products: Sales Forecast 2014-2024

8.8 Hyalein (hyaluronic acid, Santen)

8. Dry Eye Drugs Market 2014-2024

www.visiongain.com

Contents

8.8.1 Hyalein: Sales Forecast 2014-2024

8.9 Diquas (diaquafosol, Santen)

8.9.1 Diquas: Sales Forecast 2014-2024

8.10 Other Ophthalmic Drugs

8.10.1 Hetlioz (tasimelteon, Vanda Pharmaceuticals)

8.10.2 Hetlioz: Sales Forecast 2014-2024

9. Leading Companies in the Ophthalmic Drugs Market

9.1 Novartis (Alcon)

9.1.1 Novartis: Ophthalmic Drugs Portfolio

9.1.2 Novartis: Sales Forecast 2014-2024

9.1.3 Novartis: Products in Development

9.1.4 Novartis: Recent Developments

9.1.4.1 Novartis Restructures Following Strategic Review

9.1.4.2 Novartis Licenses Ophthothech’s Fovista

9.2 Allergan

9.2.1 Allergan: Ophthalmic Drugs Portfolio

9.2.2 Allergan: Sales Forecast 2014-2024

9.2.3 Allergan: Products in Development

9.2.3.1 Novadur (Intravitreal Brimonidine Implant)

9.2.4 Allergan: Recent Developments

9.2.4.1 Ozurdex (Dexamethasone Intravitreal Implant): The First Drug Therapy for

Diabetic Macular Oedema

9.2.4.2 Prospects for Generic Restasis?

9. Leading Companies in the Ophthalmic Drugs Market

www.visiongain.com

Contents

9.2.4.3 Allergan Rejects Valeant Bid

9.2.4.4 Allergan Considering Acquiring Shire?

9.3 Roche

9.3.1 Roche: Ophthalmic Drugs Portfolio

9.3.1.1 Lucentis: US Sales Forecast 2014-2024

9.3.2 Roche: Sales Forecast 2014-2024

9.3.3 Roche: Products in Development

9.4 Valeant

9.4.1 Valeant: Ophthalmic Drugs Portfolio

9.4.2 Valeant: Sales Forecast 2014-2024

9.4.3 Valeant: Products in Development

9.4.4 Valeant: Recent Developments

9.4.4.1 Valeant’s Acquisition of Bausch and Lomb: Aggressive Expansion?

9.4.4.2 Bausch and Lomb Had Acquired ISTA Pharmaceuticals

9.5 Regeneron

9.5.1 Regeneron: Ophthalmic Drugs Portfolio

9.5.2 Regeneron: Sales Forecast 2014-2024

9.5.3 Regeneron: Products in Development

9.5.4 Regeneron: Recent Developments

9.5.4.1 FDA Approves Zaltrap (aflibercept)

9.5.4.2 Eylea/Zaltrap and the Davis-Smyth Patent Agreements

9.6 Santen

9.6.1 Santen: Ophthalmic Drugs Portfolio

9.6.2 Santen: Sales Forecast 2014-2024

www.visiongain.com

Contents

9.6.3 Santen: Products in Development

9.6.4 Santen: Recent Developments

9.6.4.1 Santen Acquires Novagali Pharma

9.6.4.2 Santen Launches Alesion in Japan

9.6.4.3 Santen Acquires Merck’s Ophthalmic Drugs Portfolio

9.7 Pfizer

9.7.1 Pfizer: Ophthalmic Drugs Portfolio

9.7.1.1 Macugen (Valeant/Pfizer)

9.7.2 Pfizer: Sales Forecast 2014-2024

9.7.3 Pfizer: Products in Development

9.7.4 Pfizer: Recent Developments

9.7.4.1 Pfizer Attempts to Acquire AstraZeneca

9.8 Merck

9.8.1 Merck: Ophthalmic Drugs Portfolio

9.8.2 Merck: Sales Forecast 2014-2024

9.8.3 Merck: Products in Development

9.9 Bayer

9.9.1 Bayer: Ophthalmic Drugs Portfolio

9.9.2 Bayer: Sales Forecast 2014-2024

9.10 Senju

9.10.1 Senju: Ophthalmic Drugs Portfolio

9.10.2 Senju: Sales Forecast 2014-2024

9.10.3 Senju: Products in Development

9.10.3.1 Y-39983 (SNJ-1656)

www.visiongain.com

Contents

9.10.3.2 Difluprednate (SJE-2079)

10. Ophthalmic Drugs Pipeline Analysis 2014-2024

10.1 The Ophthalmic Drugs Pipeline: Richest in Retinal Disorder Agents

10.2 The Retinal Disorders Pipeline

10.2.1 Will Bevasiranib (RXi Pharmaceuticals) Resume Development?

10.3 Retinal Disorders: Filed or Recently Launched

10.3.1 Compaq Sipp (conbercept, Chengdu Kanghong Pharmaceutical)

10.3.2 Lipidil (fenofibrate, Abbott)

10.3.3 Iluvien (fluocinolone, Alimera)

10.4 Retinal Disorders: Phase 3 Pipeline

10.4.1 Fovista and Zimura (Ophthotech)

10.4.2 MC-1101 (hydralazine, MacuCLEAR)

10.4.3 Tandospirone (serotonin 1A agonist, Alcon)

10.4.4 UF-021 (unoprostone, R-Tech Ueno)

10.5 Retinal Disorders: Phase 2 Pipeline

10.5.1 AKB-9778 (Tie2 activator, Aerpio Therapeutics)

10.5.2 ALG-1001 (Integrin peptide therapy, Allegro/Senju)

10.5.3 AGN150998 and MP0260 (Anti-VEGF DARPins, Allergan)

10.5.4 AGN208397 (beclomethasone, Allergan)

10.5.5 CPC-551 (Colby Pharmaceutical)

10.5.6 Darapladib and GSK933776 (GSK)

10.5.7 ESBA1008 (anti-VEGF mAb, Alcon)

10.5.8 iCo-007 (antisense inhibitor of C-raf kinase mRNA, iCo Therapeutics)

10. Ophthalmic Drugs Pipeline Analysis 2014-2024

www.visiongain.com

Contents

10.5.9 iSONEP (sonepcizumab, Lpath)

10.5.10 Lampalizumab (anti-Factor D Fab, Roche)

10.5.11 LFG316 (anti-C5 mAb, Novartis)

10.5.12 Novadur (Intravitreal brimonidine implant, Allergan)

10.5.13 Optina (danazol, Ampio Pharmaceuticals)

10.5.14 PF-655 (synthetic siRNA, Quark/Pfizer)

10.5.15 Premiplex (protein replacement therapy, Shire)

10.5.16 Renexus (ciliary neurotrophic factor, Neurotech)

10.5.17 Squalamine (anti-angiogenic drug, OHR Pharmaceutical)

10.5.18 Zybrestat (fosbretabulin, Oxigene/Symphony VIDA)

10.6 Retinal Disorders: Phase 1 and Preclinical Pipeline

10.6.1 BDM-E (BioDiem)

10.6.2 NADPH Oxidase Inhibitors (Alimera)

10.6.3 NS2 (aldehyde trap, Aldeyra Therapeutics)

10.6.4 PAN-90806 (topical VEGF inhibitor, PanOptica)

10.6.5 Plasma Kallikrein Inhibitors (KalVista)

10.6.6 QLT091001 (synthetic retinoid, QLT)

10.7 Allergic, Inflammatory and Infective Drugs: Phase 3 Pipeline

10.7.1 EGP-437 (dexamethasone, EyeGate)

10.7.2 IBI-10090 and IBI-20089 (Icon Bioscience)

10.7.3 LE-MPP (loteprednol etabonate, Kala)

10.8 Allergic, Inflammatory and Infective Drugs: Phase 2 Pipeline

10.8.1 CF101 (adenosine A3 receptor agonist, Can-Fite BioPharma and OphthaliX)

10.8.2 FST-100 (povidone-iodine/dexamethasone, ForeSight Biotherapeutics)

www.visiongain.com

Contents

10.8.3 NVC-422 (auriclosene, NovaBay)

10.8.4 Sarilumab (Regeneron)

10.8.5 V404 PDS (ForSight VISION4)

10.9 Allergic, Inflammatory and Infective Drugs: Phase 1 and Preclinical Pipeline

10.9.1 Finafloxacin (MerLion Pharmaceuticals/Novartis)

10.10 Glaucoma: Phase 2 and Phase 3 Pipeline

10.10.1 Latanoprostene Bunod (BOL-303259-X, Valeant)

10.10.2 AMA0076 (ROCK inhibitor, Amakem)

10.10.3 Rhopressa (AR-13324; ROCK and NET inhibitor) and Roclatan (PG324; ROCK

inhibitor), Aerie Pharmaceuticals

10.11 Glaucoma: Phase 1 and Preclinical Pipeline

10.12 Dry Eye: Phase 3 Pipeline

10.12.1 EBI-005 (IL-1R antagonist, Eleven Biotherapeutics)

10.12.2 Lifitegrast (integrin antagonist, Shire)

10.12.3 MIM-D3 (tyrosine kinase receptor antagonist, Valeant)

10.12.4 SI-614 (modified hyaluronate, Seikagaku)

10.13 Dry Eye: Phase 2 Pipeline

10.13.1 ESBA105 (TNF-alpha antibody, Novartis/Alcon)

10.13.2 Kineret (anakinra: IL-1 receptor antagonist, Amgen/Sobi)

10.14 Other Ophthalmic Drugs Pipeline

10.14.1 Brimonidine for Eye Whitening (Valeant)

10.14.2 GS-101 (aganirsen, Gene Signal)

10.14.3 Omidria (phenylephrine/ketorolac, Omeros)

www.visiongain.com

Contents

11. Qualitative Analysis of the Ophthalmic Drugs Market 2014-2024

11.1 SWOT Analysis of the Ophthalmic Drugs Market

11.2 Strengths

11.2.1 Advances in Drug Delivery Technologies

11.2.2 Support for Reimbursement

11.2.3 Strong R&D Pipeline

11.2.3.1 Gene Therapy and RNA Interference Technology

11.2.3.2 New Ophthalmic Therapeutic Applications for Drugs

11.2.3.3 Development of Neuroprotective Anti-Glaucoma Medications

11.2.3.4 Working with Biomarkers

11.3 Weaknesses

11.3.1 Patient Adherence to Treatment

11.3.2 High Treatment Burden

11.3.3 Under-Diagnosis and Under-Treatment

11.4 Opportunities

11.4.1 Increasing Disease Prevalence

11.4.1.1 Ageing of the World Population

11.4.1.2 Increasing Prevalence of Eye Diseases and Diabetes

11.4.1.3 Glaucoma and Retinal Disorders Will Have the Most-Marked Increases in

Prevalence

11.4.2 Unmet Clinical Need in Many Disease Areas

11.4.3 Higher Growth in Emerging Markets

11.4.4 Sustained-Release Ocular Implants

11.5 Threats

11. Qualitative Analysis of the Ophthalmic Drugs Market 2014-2024

www.visiongain.com

Contents

11.5.1 Generic Competition

11.5.2 Price Regulation

11.5.3 Biosimilars

11.5.4 Increasing R&D Costs

11.6 Porter’s Five Forces Analysis of the Ophthalmic Drugs Market

11.6.1 Rivalry Among Competitors [Medium]

11.6.2 Threat of New Entrants [Low]

11.6.3 Power of Suppliers [Low]

11.6.4 Power of Buyers [Medium]

11.6.5 Threat of Substitutes [Medium]

12. Research Interviews

12.1 Interview with Cathy Yelf, Head of External Relations, Macular Society, Andover,

Hampshire, UK

12.1.1 The Work of the Macular Society

12.1.2 Developments in Treating AMD

12.1.3 Lucentis, Eylea and Avastin

12.1.4 Developments in Diagnosis of Eye Conditions

12.1.5 Unmet Needs in AMD

12.1.6 The Future of the Ophthalmic Drugs Market?

12.2 Interview with the Royal National Institute of Blind People (RNIB), London, UK

12.2.1 The Work of RNIB

12.2.2 Developments in Ophthalmology

12.2.3 Unmet Needs in Glaucoma and AMD

12. Research Interviews

www.visiongain.com

Contents


12.3 Interview with Dr Charles Wykoff, Retina Consultants of Houston, Texas, US


12.3.2 Unmet Needs in Ophthalmology

12.3.3 Regulatory Issues in the US Market


12.4 Interview with Professor Manju Subramanian, Associate Professor, Department of

Ophthalmology, Boston University School of Medicine, Boston, Massachusetts, US


12.4.2 Unmet Needs in Ophthalmology

12.4.3 Treatments for Glaucoma, AMD and Dry Eye

12.4.4 Lucentis, Eylea and Avastin

12.4.5 Jetrea for Retinal Disorders


12.5 Interview with a Spokesperson for Vanda Pharmaceuticals, Washington DC, US

12.5.1 Commercialising Hetlioz

12.5.2 Future Prospects for Vanda

12.6 Interview with Professor David T. Shima, PhD, Institute of Ophthalmology, University

College London, UK

12.6.1 On the Role of VEGF in Retinal Disorders

12.6.2 On Candidate Molecule E10030

12.6.3 On Candidate Molecule JSM 6427

12.6.4 On New Sustained Release Formulations

12.6.5 On Delta-Notch Signalling

12.6.6 Potential Clinical Crossovers Between Ophthalmology and Oncology

www.visiongain.com

Contents

12.6.7 Commercial and Clinical Possibilities in the Ophthalmology Market

12.6.8 On the Possibilities of Research into the Endothelial Fenestra

12.7 Expert Interview 7: Authority from a Company in the Industry (Views Provided

Anonymously)

12.7.1 Key Unmet Needs

12.7.2 Challenges Facing the Ophthalmic Sector

12.7.3 On Current Ophthalmic Treatments and Their Effectiveness

12.7.4 On Opportunities in the Ophthalmic Sector

12.8 Interview with Sean Ainsworth, CEO and Founder of RetroSense Therapeutics, Ann Arbor,

Michigan, USA

12.8.1 The Optogenetic Approach to Vision Restoration

12.8.2 Choosing Disease Targets and Delivery Vectors

12.8.3 The Regulatory Picture

12.8.4 Gene Therapies in AMD and Other Ophthalmic Therapeutic Areas

12.8.5 The Next Ten Years for Gene Therapy

12.9 Interview with Philip G. Ralston, Jr., CEO of MacuCLEAR, Plano, Texas, USA

12.9.1 MC-1101: Identifying and Treating Chiou Syndrome

12.9.2 Preventing Dry AMD Progression

12.9.3 Treating the Root Cause of Dry AMD

12.9.4 Phase 3: Endpoints and Prospects for MC-1101

12.10 Interview with Dr Michael Stewart, Associate Professor, Mayo Clinic, Jacksonville, Florida,

USA

12.10.1 The Impact of Eylea

12.10.2 The Comparative Dosing Schedules of Eylea and Lucentis

12.10.3 Patient Transitioning to Eylea: Salvage Switching

www.visiongain.com

Contents

12.10.4 Avastin after the CATT Study

12.10.5 Prospects for Eylea in Other Indications and Combinations

12.10.6 Future Possibilities in Wet AMD Treatment

13. Conclusions

13.1 Ophthalmic Pharmaceuticals: A Growing Niche Market

13.2 The World Ophthalmic Drugs Market in 2013

13.2.1 Current Leading Ophthalmic Drugs Segments

13.2.2 Leading Ophthalmic Drugs Products

13.2.3 Leading Ophthalmic Drugs Companies

13.2.4 Leading National Markets

13.3 World Ophthalmic Drugs Market Forecast 2014-2024

13.4 Ophthalmic Drugs Late-Stage Pipeline

13.5 The Future of the Ophthalmic Drugs Market?

13.5.1 Increasing Revenue Concentration among Specialist Companies

13.5.2 The Rise of Generics

13.5.3 Small Companies Can Have a Big Impact

13.5.4 What Will Succeed in the Ophthalmic Drugs Market?

13. Conclusions

www.visiongain.com Page 101

Ophthalmic Drugs Market Forecast 2014-2024: Prospects for Leading Companies

highest in Europe, a trend that will contribute to slowing pharmaceutical sales growth. The

tendering system and other cost-cutting measures will also restrain growth.

4.6.2 French Ophthalmic Drugs Market Forecast 2014-2024

Visiongain estimates that in 2013, the French ophthalmic drugs market reached $724m,

representing 3.7% of the world market. In 2014 the French market will increase to $742m, up 2.5%

on 2013. Table 4.9 and Figure 4.11 show visiongain’s forecast for the French ophthalmic drugs

market over 2013-2024.

Table 4.9 French Ophthalmic Drugs Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2013-2024

2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024France ($m) 724 742 760 780 795 814 831 850 868 888 912 943Annual Growth Rate (%) 2.5 2.4 2.6 1.9 2.4 2.0 2.3 2.2 2.3 2.7 3.3CAGR (%, 2013-2018 and 2018-2024)

2.4 2.5

CAGR (%, 2013-2024) 2.4

Figure 4.11 French Ophthalmic Drugs Market Forecast: Revenues ($m), AGR (%), 2013-2024

0.0

0.5

1.0

1.5

2.0

2.5

3.0

3.5

0

100

200

300

400

500

600

700

800

900

1,000

2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024

AG

R (

%)

Sal

es (

$m)

Year Sales ($m) AGR (%)

Source: visiongain 2014




revenues will reach $238m in 2024, representing a CAGR of 6.1% over 2018-2024 and an overall

CAGR of 11.1% over 2013-2024.

Table 8.7 and Figure 8.8 show visiongain’s estimates of Diquas revenues over 2013-2024.

Table 8.7 Santen: Diquas Revenue ($m), AGR (%), CAGR (%), 2013-2024

2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024Diquas ($m) 75 97 117 134 150 167 181 196 208 219 228 238 Annual Growth Rate (%) 30.0 20.0 15.0 12.0 11.1 8.5 8.0 6.5 5.2 4.2 4.0CAGR (%, 2013-2018 and 2018-2024)

17.4 6.1

CAGR (%, 2013-2024) 11.1

Figure 8.8 Santen: Diquas Revenue ($m), AGR (%), 2013-2024

8.10 Other Ophthalmic Drugs

8.10.1 Hetlioz (tasimelteon, Vanda Pharmaceuticals)

Vanda Pharmaceuticals is a biopharmaceutical company based in Washington, DC. It focuses on

developing drugs for treating CNS disorders, such as its other available drug Fanapt (iloperidone)

for schizophrenia. Hetlioz (tasimelteon) is an oral drug for the treatment of non-24-hour disorder, a

0.0

5.0

10.0

15.0

20.0

25.0

30.0

35.0

0

50

100

150

200

250

2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024

AG

R (

%)

Sal

es (

$m)






9.7.2 Pfizer: Sales Forecast 2014-2024

Table 9.15 and Figure 9.8 show visiongain’s estimates of Pfizer’s ophthalmic drug revenues over

2013-2024.

Table 9.15 Pfizer: Ophthalmic Drugs Revenue ($m), AGR (%), CAGR (%), 2013-2024

2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024

Pfizer ($m) 595 469 399 281 240 228 226 231 237 244 251 259

Annual Growth Rate (%) -21.2 -14.8 -29.5 -14.7 -4.9 -1.0 1.9 2.9 2.9 2.9 2.9CAGR (%, 2013-2018 and 2018-2024)

-17.4 2.1

CAGR (%, 2013-2024) -7.3

Figure 9.8 Pfizer: Ophthalmic Drugs Revenue ($m), AGR (%), 2013-2024

Pfizer’s ophthalmic drug revenues peaked in 2010, reaching an estimated $1,758m largely due to

sales of Xalatan and Xalacom. However, revenues have since fallen to reach $595m in 2013, a

CAGR of -30.3% over 2010-2013 mirroring the decline in revenues from Xalatan/Xalacom. This

decline was primarily due to generic competition for Xalatan/Xalacom, which lost patent protection

in all major pharmaceutical markets. Xalatan lost exclusivity in the US in March 2011 and Pfizer

further lost exclusivity for Xalatan and Xalacom in 15 major European markets in January 2012.

-35.0

-30.0

-25.0

-20.0

-15.0

-10.0

-5.0

0.0

5.0

0

100

200

300

400

500

600

700

2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024

AG

R (

%)

Sal

es (

$m)




ophthalmic drugs market 2014-2024

Business

intravitreal

ophthalmic

ophthalmic

ophthalmic

ophthalmic

leading companies

ophthalmic

infective